Zacks Investment Management reduced its holdings in shares of FibroGen, Inc (NASDAQ:FGEN) by 47.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,110 shares of the biopharmaceutical company’s stock after selling 7,237 shares during the period. Zacks Investment Management’s holdings in FibroGen were worth $262,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of FGEN. BlackRock Inc. grew its holdings in FibroGen by 29,724.1% during the 1st quarter. BlackRock Inc. now owns 4,454,819 shares of the biopharmaceutical company’s stock worth $109,811,000 after acquiring an additional 4,439,882 shares during the period. FMR LLC grew its holdings in FibroGen by 96.9% during the 2nd quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock worth $107,753,000 after acquiring an additional 1,641,423 shares during the period. Vanguard Group Inc. grew its holdings in FibroGen by 15.1% during the 2nd quarter. Vanguard Group Inc. now owns 5,808,439 shares of the biopharmaceutical company’s stock worth $187,612,000 after acquiring an additional 761,421 shares during the period. Prudential Financial Inc. grew its holdings in FibroGen by 95.2% during the 1st quarter. Prudential Financial Inc. now owns 409,350 shares of the biopharmaceutical company’s stock worth $10,090,000 after acquiring an additional 199,670 shares during the period. Finally, UBS Asset Management Americas Inc. grew its holdings in FibroGen by 1,687.2% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 209,155 shares of the biopharmaceutical company’s stock worth $6,756,000 after acquiring an additional 197,452 shares during the period. Hedge funds and other institutional investors own 47.49% of the company’s stock.

FibroGen, Inc (FGEN) opened at 56.70 on Friday. The company’s market cap is $4.04 billion. The company has a 50-day moving average of $49.37 and a 200 day moving average of $34.92. FibroGen, Inc has a 12 month low of $15.60 and a 12 month high of $60.15.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($0.01). The business had revenue of $29.00 million during the quarter, compared to analysts’ expectations of $34.80 million. FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. On average, equities analysts forecast that FibroGen, Inc will post ($1.80) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “FibroGen, Inc (FGEN) Holdings Trimmed by Zacks Investment Management” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/10/06/fibrogen-inc-fgen-holdings-trimmed-by-zacks-investment-management.html.

Several analysts have recently commented on the company. Stifel Nicolaus restated a “buy” rating and issued a $38.00 target price (up from $32.00) on shares of FibroGen in a research note on Thursday, June 22nd. BidaskClub upgraded FibroGen from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 24th. William Blair restated an “outperform” rating on shares of FibroGen in a research note on Monday, June 26th. Citigroup Inc. restated a “buy” rating and issued a $48.00 target price on shares of FibroGen in a research note on Monday, June 26th. Finally, Jefferies Group LLC assumed coverage on FibroGen in a research note on Monday, July 10th. They issued a “buy” rating and a $50.00 target price for the company. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $65.67.

In other news, Director Kalevi Kurkijarvi sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $33.45, for a total value of $66,900.00. Following the transaction, the director now owns 32,000 shares in the company, valued at $1,070,400. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Pat Cotroneo sold 28,346 shares of the company’s stock in a transaction that occurred on Wednesday, August 2nd. The stock was sold at an average price of $33.97, for a total transaction of $962,913.62. Following the completion of the transaction, the vice president now owns 170,666 shares in the company, valued at approximately $5,797,524.02. The disclosure for this sale can be found here. In the last 90 days, insiders sold 542,828 shares of company stock worth $25,858,047. Corporate insiders own 14.90% of the company’s stock.

FibroGen Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Stock Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related stocks with our FREE daily email newsletter.